Milestone Pharmaceuticals Q3 2021 Earnings Report
Key Takeaways
Milestone Pharmaceuticals reported their third quarter financial results, highlighting the progress of the etripamil PSVT program and the advancement of Phase 3 efficacy and safety studies. They also completed patient research to understand the burden experienced by patients. Data from an analysis of heart rate in patients treated in the NODE-301 trial will be presented at the AHA Scientific Sessions 2021 meeting.
Continued progress across etripamil PSVT program.
Advanced Phase 3 efficacy and safety studies.
Completed important patient research for deeper understanding of patient burden.
Data from NODE-301 trial will be presented at AHA Scientific Sessions 2021.
Milestone Pharmaceuticals
Milestone Pharmaceuticals
Forward Guidance
The press release contains forward-looking statements regarding the potential of etripamil, the design, progress, timing, scope and results of the RAPID and ReVeRA trials, Milestone’s ability to execute on the remainder of the PSVT program, Milestone’s ongoing plans to study etripamil in atrial fibrillation patients, the sufficiency of Milestone’s current cash resources to support its operations, and estimates about the addressable market and commercial potential for treatments of atrial fibrillation with rapid ventricular rate.